ReviewChemical Society reviews2018
Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics.
Review in Chemical Society reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- A NIR fluorotag reporter CETIF6a enables bright pan-tumor labeling and functional proteomic profiling.Nature communications · 2026Article
- An extrinsic enzyme-activatable fluorescent probe for high-contrast tumor imaging.Chemical science · 2026Article
- Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.Nature communications · 2026Article
- Glutathione responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics.Discover oncology · 2026Review
- Cell surface engineering via self-assembly DNA networks for cell behavior control.Frontiers in bioengineering and biotechnology · 2026Article
- Brightening New Horizons: Luminescent Transition Metal Complexes in Optical Imaging and Theranostic Applications.ACS central science · 2025Review
- Recent advancements in molecular photoacoustic tomography.JPhys photonics · 2025Review
- An activatable unimolecular phototheranostic agent for synergistic chemo-photodynamic therapy.Chemical science · 2025Article
- Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells andJournal of medicinal chemistry · 2024Article
- γ-Glutamyltranspeptidase (GGT) Sensitive Fluorescence Probes for Cancer Diagnosis; Brief Review.Journal of fluorescence · 2024Review
- Article
- Detection of breast cancer cells by a near-infrared fluorescent probe targeting mitochondrial viscosity.Heliyon · 2023Article
- Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Pillararenes as Promising Carriers for Drug Delivery.International journal of molecular sciences · 2023Review
- Fluorescent Probes as a Tool in Diagnostic and Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Cooperatively enhanced photothermal-chemotherapyChemical science · 2023Article
- Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.International journal of molecular sciences · 2023Review
- Synthesis and Characterization of Fluorescence Active GChinese chemical letters = Zhongguo hua xue kuai bao · 2022Article
- NIR fluorescence imaging and treatment for cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Theranostic systems are receiving ever-increasing attention due to their potential therapeutic utility, imaging enhancement capability, and promise for advancing the field of personalized medicine, particularly as it relates to the diagnosis, staging, and treatment of cancer. In this Tutorial Review, we provide an introduction to the concepts of theranostic drug delivery effected via use of conjugates that are able to target cancer cells selectively, provide cytotoxic chemotherapeutics, and produce readily monitored imaging signals in vitro and in vivo. The underlying design concepts, requiring the synthesis of conjugates composed of imaging reporters, masked chemotherapeutic drugs, cleavable linkers, and cancer targeting ligands, are discussed. Particular emphasis is placed on highlighting the potential benefits of fluorogenic reaction-based targeted systems that are activated for both imaging and therapy by cellular entities, e.g., thiols, reactive oxygen species and enzymes, which are present at relatively elevated levels in tumour environments, physiological characteristics of cancer, e.g., hypoxia and acidic pH. Also discussed are systems activated by an external stimulus, such as light. The work summarized in this Tutorial Review will help define the role fluorogenic reaction-based, cancer-targeting theranostics may have in advancing drug discovery efforts, as well as improving our understanding of cellular uptake and drug release mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.